GlassScriptPhysician profile
Ahmad Goodarzi
NPI 1992012173
$9,399.89
in general payments reported to CMS, 2019-2025
33 companies · $1,913 in 2025
The $1,913 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $153 · 2021: $207 · 2022: $3,902 · 2023: $1,077 · 2024: $1,532 · 2025: $1,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,343.91 |
| Education | $177.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,000.00 | 2022 | |
| Insmed, INC. | $1,102.29 | 2019-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $642.44 | 2019-2025 | Ofev, Jascayd |
| Ethicon INC. | $605.85 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $582.31 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Astellas Pharma US INC | $483.71 | 2019-2025 | Cresemba |
| United Therapeutics Corporation | $451.53 | 2019-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $349.41 | 2019-2025 | Prolastin-C Liquid |
| Paragonix Technologies, INC. | $260.83 | 2024 | Lungguard, Baroguard, Liverguard |
| Baxter Healthcare | $255.21 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Takeda Pharmaceuticals U.S.A., INC. | $178.96 | 2022-2025 | Aralast, Glassia |
| Mylan Specialty L.P. | $167.92 | 2019-2024 | Yupelri |
| Pfizer INC. | $144.42 | 2021-2025 | |
| Glaxosmithkline, LLC. | $143.83 | 2020-2025 | Nucala, Shingrix, Trelegy Ellipta |
| Shionogi INC | $112.24 | 2024-2025 | Fetroja |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $100.47 | 2023-2024 | Dupixent |
| Viatris Specialty LLC | $97.55 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $95.44 | 2024-2025 | Purified Cortrophin Gel |
| Electromed, INC. | $93.33 | 2023-2024 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $77.51 | 2022-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $66.92 | 2019-2025 | Winrevair |
| Sandoz INC. | $59.47 | 2019-2023 | Treprostinil |
| Bayer Healthcare Pharmaceuticals INC. | $56.57 | 2023 | |
| Pulmonx Corporation | $53.23 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Allergan, INC. | $43.93 | 2019 | |
| Mallinckrodt Hospital Products INC. | $40.08 | 2023-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $35.72 | 2024-2025 | Ultomiris |
| Genzyme Corporation | $20.80 | 2023 | |
| Alcresta Therapeutics, INC. | $20.63 | 2024 | Relizorb |
| Inogen, INC. | $20.26 | 2025 | |
| Advanced Respiratory, INC | $18.64 | 2019 | |
| Pharming Healthcare, INC. | $18.39 | 2024 | Ruconest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Goodarzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.